Kenvue stock (US49177J1025): shares steady as NYSE trading highlights valuation debate

Kenvue’s stock traded in the high-teens in USD on the New York Stock Exchange on 05/29/2026, leaving the consumer health group broadly in line with levels seen after its most recent earnings release, according to NYSE price data as of 05/29/2026 and coverage collated by MarketBeat.

The company, which is headquartered in the United States and listed under the ticker KVUE in New York, has attracted renewed attention from US investors as it continues to trade around the high-teens while analysts’ 12-month price targets sit close to the low-20s in USD, based on data from MarketBeat as of 05/29/2026 and a TradingView summary of analyst estimates dated 05/2026.

The stock traded at about USD 17.66 on 05/29/2026 on the NYSE, according to MarketBeat’s Kenvue price performance snapshot as of 05/29/2026, with the issue continuing to reflect a mid-cap consumer health profile in the United States. In Germany, the shares are also available via Tradegate in EUR for investors seeking local-market access, according to Tradegate price quotations as of 05/29/2026.

Kenvue’s most recently reported quarterly earnings showed diluted EPS of USD 0.32 for the period, compared with consensus expectations of USD 0.27 at the time, according to a MarketBeat recap of the latest quarterly release as of 05/29/2026, underscoring the group’s ability to generate steady cash flow in a challenging consumer backdrop. The same source reported a return on equity of 20.81 percent and a net margin of 9.63 percent for that quarter, as summarized by MarketBeat on 05/29/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Kenvue: core business model

Kenvue focuses on branded consumer health products, drawing most of its revenue from over-the-counter medicines, skincare, and personal care labels that target everyday wellness needs worldwide.

Valuation metrics and multiples for Kenvue

Public data compiled by MarketBeat as of 05/29/2026 indicate that Kenvue currently carries a consensus rating of "Hold" and a consensus price target of about USD 19.33, based on analyst coverage summarized in late 05/2026. A TradingView note dated 05/2026 similarly points to an average 12-month target of roughly USD 19.30, with individual forecasts ranging from USD 18 to USD 22, suggesting modest expected upside versus the mid-teens share price range at which the stock traded on 05/29/2026.

On that basis, Kenvue’s implied valuation reflects its positioning as a defensive consumer health issuer with established brands, where analysts expect incremental upside driven by earnings stability rather than aggressive growth, according to the MarketBeat consensus snapshot and the TradingView compilation of 10 analyst estimates as of 05/2026. While detailed forward P/E or EV/EBITDA metrics were not disclosed in those summaries, the gap between current trading levels near USD 17.66 and the clustered targets around USD 19 to USD 22 illustrates the market’s relatively cautious stance on multiple expansion.

Conclusion

The latest NYSE trading data show Kenvue’s stock broadly stable in the high-teens in USD, even after a quarter in which the consumer health group delivered EPS of USD 0.32 versus a USD 0.27 consensus estimate and reported double-digit return on equity, as recapped by MarketBeat for the most recent period. Valuation indicators from MarketBeat and TradingView as of 05/2026 highlight a consensus price target just under USD 20 and a "Hold" stance, implying that analysts currently expect only incremental upside as the company leans on its portfolio of everyday health brands and earnings resilience. How the shares trade relative to these clustered targets will likely depend on Kenvue’s ability to sustain margin performance and cash generation in upcoming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.